Risk Measures And Screening - USMLE Step 1

1. Which of the following statements is the most accurate summary of these results?
   Answer: The number needed to treat to have one additional person quit is 10. The number needed to treat (NNT) is the reciprocal of the absolute risk reduction (or absolute benefit increase). The absolute benefit is the difference in quit rates: 15% - 5% = 10% or 0.10. The NNT = 1 / 0.10 = 10. This means that for every 10 people who receive the intervention, one additional person will quit smoking compared to placebo. The other options are incorrect: the relative risk of remaining a smoker is (1-0.15)/(1-0.05) = 0.85/0.95 = 0.89 (not 0.85); the relative benefit is (15%-5%)/5% = 200%; and the intervention increases the quit rate by a factor of 3 (15%/5%), not 2.
2. This NNT value is the reciprocal of which of the following?
   Answer: Absolute risk reduction The number needed to treat (NNT) is a measure of the effectiveness of an intervention. It is mathematically defined as the inverse of the absolute risk reduction (ARR). The formula is NNT = 1 / ARR. Therefore, if the NNT is 30, the ARR is 1/30 or approximately 3.3%.
3. Based on this information, which of the following is the most accurate conclusion?
   Answer: Drug A is more effective than Drug B. The number needed to treat (NNT) represents the number of patients who need to receive an intervention to prevent one additional adverse outcome. A lower NNT indicates a more effective intervention. Therefore, Drug A (NNT=25) is more effective than Drug B (NNT=75), as fewer patients need to be treated with Drug A to achieve the same benefit.
4. What is the number needed to treat (NNT) to prevent one severe migraine over one year with this new drug?
   Answer: 20 The number needed to treat (NNT) is the reciprocal of the absolute risk reduction (ARR). First, calculate the ARR: ARR = (Risk in control group) - (Risk in treatment group) = 15% - 10% = 5% or 0.05. Then, calculate the NNT: NNT = 1 / ARR = 1 / 0.05 = 20. This means 20 patients need to be treated for one year to prevent one severe migraine.
5. Which of the following characteristics would most strongly support the implementation of a screening program?
   Answer: Treatment is most effective when initiated in the early, asymptomatic stage. A key principle of screening is that early detection must lead to a better health outcome. Therefore, a disease is suitable for screening if treatment initiated in the early, asymptomatic (preclinical) stage is more effective than treatment started after symptoms appear. A long preclinical phase (not short) is also favorable as it provides a window for detection.
6. What is the most significant problem with implementing this screening program in the general population?
   Answer: A low positive predictive value. When a disease is rare, even a test with high specificity will produce a large number of false positives relative to true positives. This results in a low positive predictive value (PPV), which is the probability that a person with a positive test result truly has the disease. A low PPV means that most positive results will be false, leading to unnecessary anxiety, cost, and invasive follow-up procedures for many healthy individuals.
7. A 50-year-old woman has mammography screening (sensitivity 90%, specificity 91%). Which of the following reflects the test's sensitivity?​
   Answer: True positives among all with cancer This question tests understanding of risk measures and screening (USMLE Step 1). Risk measures like sensitivity and specificity help understand test accuracy and implications on patient care. In this vignette, sensitivity is key to determining the test's ability to identify disease presence accurately. Choice A is correct because it reflects the test's sensitivity, defined as true positives among all with the disease. Choice B is incorrect due to misrepresenting sensitivity, as it would imply false negatives among diseased. Teaching strategies include focusing on understanding test characteristics like sensitivity and specificity, and applying them to patient care scenarios. Use 2x2 tables to calculate and visualize these measures in different prevalence settings.
8. Which statement provides the most clinically relevant perspective on the drug's efficacy for an individual patient?
   Answer: The absolute risk reduction is very small, suggesting a limited clinical impact. While the relative risk reduction (50%) sounds impressive, the absolute risk reduction (ARR) provides a better perspective on the actual clinical impact. An ARR of 0.001% (or 1 in 100,000) is extremely small. This means that 100,000 people would need to be treated for one year to prevent one death. For an individual patient, this represents a very small chance of benefit, highlighting the limited clinical impact despite a large relative effect.
9. A 60-year-old man considers statins. Without treatment, 10-year MI risk is 20%; with statins it is 15% (ARR 5%, RRR 25%). Which statement about the number needed to treat (NNT) is correct?​
   Answer: NNT is $1/0.05=20$ This question tests understanding of risk measures and screening (USMLE Step 1). Risk measures like absolute risk reduction (ARR), relative risk reduction (RRR), and number needed to treat (NNT) help quantify treatment benefits and inform clinical decisions. In this vignette, NNT is key to determining how many patients need statin therapy to prevent one myocardial infarction over 10 years. Choice B is correct because NNT is calculated as 1/ARR, which is 1/0.05 = 20. Choice A is incorrect due to mistakenly using RRR (0.25) instead of ARR in the NNT formula. Teaching strategies include memorizing the formulas for ARR, RRR, and NNT, and practicing their application in patient scenarios to appreciate how baseline risk influences treatment impact. Additionally, discuss these measures in shared decision-making to balance benefits and potential side effects.
10. The claim in the advertisement is based on which of the following measures?
    Answer: Relative risk reduction Relative risk reduction (RRR) quantifies the percentage reduction in risk in the treated group relative to the control group. It is calculated as 1 - RR. In this case, RRR = 1 - 0.75 = 0.25, or 25%. This measure is often used in advertising because it can sound more impressive than the absolute risk reduction, especially when the baseline risk is low.
11. What is the number of patients that must be treated for 5 years to prevent one MACE?
    Answer: 50 The number needed to treat (NNT) is the reciprocal of the absolute risk reduction (ARR). First, calculate the ARR. ARR = Risk(placebo) - Risk(treatment) = 6% - 4% = 2% = 0.02. Next, calculate the NNT. NNT = 1 / ARR = 1 / 0.02 = 50. Therefore, 50 patients need to be treated for 5 years to prevent one major adverse cardiac event.
12. Which of the following biases is the most likely explanation for the better survival outcomes in the screened group?
    Answer: Length-time bias Length-time bias occurs when screening tests are more likely to detect slow-growing, less aggressive forms of a disease, which have a longer asymptomatic period and inherently better prognosis. This overestimates the effectiveness of the screening program because it preferentially selects for cases with better outcomes, regardless of the intervention.
13. Which of the following is the most accurate interpretation of this finding?
    Answer: The risk of developing diabetes is 80% higher for consumers of these beverages. A relative risk (RR) of 1.8 means that the exposed group (consumers of sugar-sweetened beverages) is 1.8 times as likely to develop the outcome (diabetes) as the unexposed group. This can be expressed as an 80% increase in risk (RR of 1.0 means no change in risk; 1.8 - 1.0 = 0.8, or an 80% increase).
14. What is the absolute risk reduction (ARR) for stroke with the new medication?
    Answer: 2% Absolute risk reduction (ARR) is the difference in the event rate between the control group and the treatment group. The event rate in the control group is 50/1000 = 5%. The event rate in the treatment group is 30/1000 = 3%. ARR = (Risk in control) - (Risk in treatment) = 5% - 3% = 2%.
15. A 60-year-old man starts statins. Trial data: MI risk 6% with placebo vs 4% with statin over 10 years (ARR 2%, RRR 33%). Which statement about the number needed to treat (NNT) is correct?​
    Answer: NNT is $1/0.02=50$ This question tests understanding of risk measures and screening (USMLE Step 1). Risk measures like absolute risk reduction (ARR), relative risk reduction (RRR), and number needed to treat (NNT) help quantify treatment benefits and inform clinical decisions. In this vignette, NNT is key to determining how many patients need statin therapy to prevent one myocardial infarction over 10 years. Choice A is correct because NNT is calculated as 1/ARR, which is 1/0.02 = 50. Choice B is incorrect due to mistakenly using RRR (0.33) instead of ARR in the NNT formula. Teaching strategies include memorizing the formulas for ARR, RRR, and NNT, and practicing their application in patient scenarios to appreciate how baseline risk influences treatment impact. Additionally, discuss these measures in shared decision-making to balance benefits and potential side effects.
16. A 50-year-old woman undergoes screening mammography (sensitivity 90%, specificity 91%). In this clinic, breast cancer prevalence is 1%. Which of the following reflects the test's sensitivity?​
    Answer: P(test+ | disease present) This question tests understanding of risk measures and screening (USMLE Step 1). Risk measures like sensitivity and specificity help understand test accuracy and implications on patient care. In this vignette, sensitivity is key to determining the test's ability to identify disease presence accurately. Choice A is correct because it reflects the test's sensitivity, defined as the probability of a positive test given the disease is present. Choice B is incorrect due to misunderstanding sensitivity's role, as it actually represents the false-negative rate. Teaching strategies include focusing on understanding test characteristics like sensitivity and specificity, and applying them to patient care scenarios. Use 2x2 tables to calculate and visualize these measures in different prevalence settings.
17. A 60-year-old man has baseline 10-year MI risk 30%; statin lowers it to 24% (ARR 6%, RRR 20%). Which statement about the number needed to treat (NNT) is correct?​
    Answer: NNT is $1/0.06\approx17$ This question tests understanding of risk measures and screening (USMLE Step 1). Risk measures like absolute risk reduction (ARR), relative risk reduction (RRR), and number needed to treat (NNT) help quantify treatment benefits and inform clinical decisions. In this vignette, NNT is key to determining how many patients need statin therapy to prevent one myocardial infarction over 10 years. Choice B is correct because NNT is calculated as 1/ARR, which is 1/0.06 ≈ 17. Choice A is incorrect due to mistakenly using an incorrect ARR value. Teaching strategies include memorizing the formulas for ARR, RRR, and NNT, and practicing their application in patient scenarios to appreciate how baseline risk influences treatment impact. Additionally, discuss these measures in shared decision-making to balance benefits and potential side effects.
18. What is the relative risk reduction (RRR) of DVT with the new anticoagulant?
    Answer: 40% Relative risk reduction (RRR) is the proportion of risk reduction attributable to the intervention compared to a control. RRR = (Risk in control - Risk in treatment) / Risk in control. ARR = 10% - 6% = 4%. RRR = 4% / 10% = 0.40, or 40%. Alternatively, Relative Risk (RR) = 6%/10% = 0.6. RRR = 1 - RR = 1 - 0.6 = 0.4 or 40%.
19. Which of the following biases best explains the apparent increase in 5-year survival?
    Answer: Lead-time bias Lead-time bias occurs when a screening test detects a disease earlier than it would have been detected by clinical symptoms. This increases the measured survival time from diagnosis, even if the treatment does not prolong life. The fact that the overall mortality rate is unchanged suggests that the early diagnosis did not alter the ultimate outcome, which is the hallmark of lead-time bias.
20. Which of the following concepts best explains the increased incidence without a change in mortality?
    Answer: Overdiagnosis Overdiagnosis is the detection of 'disease' that would never have caused symptoms or death. The highly sensitive test is likely identifying many indolent or non-progressive tumors that are clinically insignificant. This increases the number of diagnosed cases (incidence) but does not impact the mortality rate because these tumors were not destined to be lethal.

Start this quiz